ApoE4 Function in Alzheimer's Disease

Overview

This experiment investigates how Apolipoprotein E4 (ApoE4) confers increased AD risk at the cellular level. ApoE4 is the strongest genetic risk factor for late-onset AD, with one copy increasing risk ~3x and two copies ~12x. The mechanism by which ApoE4 increases AD risk remains incompletely understood.

Pathway / Mechanism Diagram

Research Question

AD Gap #17: How does ApoE4 confer risk at the cellular level?

What are the cellular mechanisms by which ApoE4 promotes Aβ aggregation, neuroinflammation, and neurodegeneration, and can these be therapeutically targeted?

Hypothesis

Overview

This experiment investigates how Apolipoprotein E4 (ApoE4) confers increased AD risk at the cellular level. ApoE4 is the strongest genetic risk factor for late-onset AD, with one copy increasing risk ~3x and two copies ~12x. The mechanism by which ApoE4 increases AD risk remains incompletely understood.

Pathway / Mechanism Diagram

Research Question

AD Gap #17: How does ApoE4 confer risk at the cellular level?

What are the cellular mechanisms by which ApoE4 promotes Aβ aggregation, neuroinflammation, and neurodegeneration, and can these be therapeutically targeted?

Hypothesis

ApoE4 promotes AD pathogenesis through multiple mechanisms: enhanced Aβ binding and aggregation seeding, impaired Aβ clearance across the BBB, gain of neurotoxic lipoproteins, and amplified neuroinflammation via microglial dysregulation. Targeting these mechanisms will reduce AD risk in ApoE4 carriers.

Experimental Design

Model System

• In vitro: Astrocyte and neuron cultures from ApoE4-TR and ApoE3-TR iPSC lines
• Animal: ApoE knock-in mice (ApoE3/E3, ApoE3/E4, ApoE4/E4)
• Human: ApoE4 carrier vs non-carrier iPSC-derived brain cells

Validation Protocol

Phase 1: ApoE4-Aβ Interaction Mapping

Phase 2: Cellular Mechanisms

Phase 3: In Vivo Validation

Phase 4: Therapeutic Targeting

Expected Outcomes

Feasibility Assessment

| Factor | Rating | Notes |
|--------|-------|-------|
| Technical feasibility | 8/10 | iPSC and mouse models well-established; ApoE4-KI mice available |
| Cost efficiency | 7/10 | Standard assays; gene therapy adds cost |
| Timeline | 18 months | Phases 1-2 (6 mo) + in vivo (9 mo) + therapy (6 mo) |
| Cross-disease value | 8/10 | Relevance to other ApoE-associated conditions |

Cost Estimate

| Component | Cost (USD) |
|-----------|------------|
| Personnel (3 FTE × 18 mo) | $450,000 |
| iPSC differentiation and characterization | $120,000 |
| ApoE4-KI mice (200) | $80,000 |
| RNA-seq and lipidomics | $100,000 |
| PET imaging | $60,000 |
| ApoE4 correctors | $40,000 |
| Total | $850,000 |

Key References

Score

Total Score: 75 (Rank 68)

| Dimension | Score |
|-----------|-------|
| Mechanistic Impact | 9 |
| Cure Proximity | 7 |
| Feasibility | 7 |
| Cost Efficiency | 7 |
| Timeline | 6 |
| Cross-Disease Value | 8 |
| Biomarker Enablement | 6 |
| Combinability | 7 |
| De-risking Value | 8 |
| Novelty | 6 |

Addressed Gap

• AD Knowledge Gap #17: How does ApoE4 confer risk at the cellular level?

See Also

• [TREM2 Function in AD](/experiments/trem2-function-alzheimers)](/experiments)
• [Microbiome-Gut-Brain Axis in AD](/experiments/microbiome-gut-axis-alzheimers)](/experiments)
• [AD Knowledge Gaps Ranked](/gaps/ad-knowledge-gaps-ranked)